Skip to main content
. 2022 Jun 14;29(4):570–578. doi: 10.1093/ibd/izac121

Figure 3.

Figure 3.

SCCAI subscores for stool frequency (A), bleeding (B), and urgency (C) during the initial 56 days of treatment with tofacitinib. In each panel are shown the percentage of patients with improvement of ≥1 point compared to the baseline SCCAI subscores well as the percentage of patients with a subscore of ≤1 and 0.